Bismuth-containing compounds in topical dosage forms

摘要

Use of a pharmaceutically acceptable bismuth compound in the manufacture of a medicament in a topical dosage form for the reduction or eradication of H.pylori from dental plaque and gastric mucosa, wherein said topical dosage form provides controlled release of the bismuth compound in the oral cavity for at least 5 minutes in a therapeutically-effective amount of at least 2 times the minimum inhibitory concentration for H.pylori.